加载中
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
NASDAQHealthcareDrug Manufacturers - General
最新数据
US$2.92
−US$0.04 · -1.35%
前收盘价
US$2.92
−US$0.04 · -1.35%
盘前
US$3.01
+US$0.09 · +3.08%
10月12日 7:49 ET
盘中时间采用ET。市场数据可能有所延迟。
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
日内区间
当前US$2.92
52周区间
当前US$2.92
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3025.3万 USD | 5659万 USD | 4674.3万 USD | 3803.4万 USD | 3131.7万 USD |
| 销货成本 | 1522.2万 USD | 1668.9万 USD | 1568.1万 USD | 1079.7万 USD | 363.4万 USD |
| 毛利 | 1503.1万 USD | 3990.1万 USD | 3106.2万 USD | 2723.7万 USD | 2768.3万 USD |
| 研究与开发 | 2071万 USD | 964.1万 USD | 1274.6万 USD | 905.4万 USD | 920.1万 USD |
| 销售、一般及管理费用 | 2.67亿 USD | 1.19亿 USD | 1.2亿 USD | 6489.5万 USD | 5058.2万 USD |
| 营业费用 | 2.87亿 USD | 1.23亿 USD | 1.36亿 USD | 7787.1万 USD | 6352.1万 USD |
| 利息支出 | 1145.9万 USD | 196.3万 USD | 106.8万 USD | 960.4万 USD | 1176.4万 USD |
| 折旧和摊销 | 462.3万 USD | 404.6万 USD | 414.6万 USD | 396.1万 USD | 377.9万 USD |
| 营业利润 | −2.72亿 USD | −8339.6万 USD | −1.05亿 USD | −5063.4万 USD | −3583.8万 USD |
| 净利润 | −3.59亿 USD | −7280.7万 USD | −1.14亿 USD | −2336.4万 USD | −8842.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月15日 | 1:35 | — | — |
已生效 2025年4月15日
1:35
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI119.52万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF41.89万0.00%954亿 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC7.08万0.01%13.17亿 USD0.60%US$183+0.11%
Avantis Total Equity Markets ETF 1AVTM236.8—7.94亿 USD0.23%US$55.6085+0.56%
Dimensional - US Core Equity Market ETFDFAU195.360.00%131.2亿 USD0.12%US$53.43+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis Total Equity Markets ETF 1AVTMDimensional - US Core Equity Market ETFDFAUAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
